Aura Biosciences (AURA) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
20 Apr, 2026Voting matters and shareholder proposals
Election of two Class II directors, David Johnson and Teresa Marie Bitetti, to serve until the 2029 annual meeting or until a successor is elected or qualified.
Ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Additional business may be addressed if properly brought before the meeting or any adjournment.
Board of directors and corporate governance
Board recommends voting in favor of both director nominees and the auditor ratification.
Audit committee and external auditor matters
Proposal to ratify Ernst & Young LLP as the external auditor for the 2026 fiscal year.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Aura Biosciences
- CEO transition, clinical trial progress, and capital actions mark a pivotal period for the company.AURA
Proxy filing4 May 2026 - 2026 meeting to elect directors, ratify auditor, and highlight governance and compensation updates.AURA
Proxy filing20 Apr 2026 - Bel-sar delivers high tumor control and vision preservation, pioneering new standards in cancer care.AURA
Corporate presentation30 Mar 2026 - Lead trial enrollment accelerates, cash runway extends into 2027, net loss rises to $106M.AURA
Q4 202530 Mar 2026 - Phase III ocular oncology drug nears enrollment completion, with major data due in Q4 2027.AURA
Leerink Global Healthcare Conference 202610 Mar 2026 - Phase III ocular melanoma trial on track, with expanding market and strong safety profile.AURA
TD Cowen 46th Annual Health Care Conference4 Mar 2026 - Precision therapy shows durable tumor control in ocular and bladder cancers, with key data ahead.AURA
Jefferies 2024 Global Healthcare Conference1 Feb 2026 - Late-stage oncology trials show strong efficacy and safety, with major data readouts imminent.AURA
H.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026 - 80% tumor control and 90% vision preservation at 12 months, with strong safety profile.AURA
Status Update20 Jan 2026